Bpifrance, Kurma Partners, Angelini Pharma, Evotec, and Institut Pasteur led a $59m investment in Argobio, start-up studio dedicated to life sciences. “Building on our BRIDGE strategy and partnerships, we continue to be dedicated to making Evotec’s all-modality technology platforms available to validate and accelerate therapeutic concepts from toptier academic institutions globally. As an investor into Argobio, we are delighted to work with a group of distinguished partners and entrepreneurs to build companies committed to the maturation of first-in-class therapeutics towards drugs that which will change patients’ lives and cure diseases with some of the highest medical needs,” Werner Lanthaler, Evotec CEO.